Thakral Beenu, Marwaha Neelam, Chawla Y K, Saluja Karan, Sharma Arpita, Sharma R R, Minz R W, Agnihotri S K
Departments of Transfusion Medicine, Postgraduate Institute of Medical Education & Research, Chandigarh, India.
Indian J Med Res. 2006 Oct;124(4):431-8.
BACKGROUND & OBJECTIVES: The clinical significance of anti HCV antibodies in healthy blood donors remains uncertain. These donors are usually asymptomatic and it is difficult to elicit risk factors of acquiring HCV infection during pre-donation questioning. Limited information on donor recall and follow up studies on anti HCV positive blood donors have been reported from India. Paucity of data which is likely to have an impact on safe blood transfusion programme has prompted us to undertake this study to assess the significance of HCV seropositivity in blood donors with respect to their clinical, biochemical and virological profile.
A total of 16,250 blood units were screened for the mandatory tests using third generation ELISA (anti HIV 1&2, anti HCV, HBsAg), VDRL and peripheral smear for malaria. Donors reactive for anti HCV were informed. Repeat anti HCV reactive donors were subjected to detailed clinical history focusing on risk factors for HCV transmission. The blood tests included liver function tests (LFT), coagulation and autoimmune profile, qualitative serum cryoglobulins and HCV RNA detection. These donors were followed at 2-3 monthly intervals for a minimum period of six months by LFT.
An overall seropositivity of 0.44 per cent (72/16,250) was observed in our donors which was significantly lower in first time, young voluntary donors as compared to replacement donors (0.27 vs. 0.60%). In contrast to drug abuse (6.4%) we found minor percutaneous routes like sharing of shaving kits or visit to a road side barber (32%) as the major risk factor for HCV transmission. There was no prior history of blood transfusion in any of these donors; however history of some surgical procedures was present in 25.8 per cent. Raised transaminases and HCV viraemia were observed in 87 and 71 per cent donors respectively. An association was observed between HCV RNA when the ELISA ratio was >5.
INTERPRETATION & CONCLUSION: Voluntary donors form a safe source of blood supply and efforts should be made to increase this precious source to 100 per cent. Abbreviated behavioural donor screening questionnaire for repeat donors is not advisable. Awareness and education of donors is required regarding modes of HCV transmission. HCV positive donors should be informed about their disease, counselled and referred to hepatologist, and permanently deferred for future donations.
健康献血者中抗丙型肝炎病毒(HCV)抗体的临床意义仍不明确。这些献血者通常没有症状,且在献血前询问时很难找出感染HCV的危险因素。印度关于献血者召回及抗HCV阳性献血者随访研究的信息有限。由于缺乏可能影响安全输血计划的数据,促使我们开展这项研究,以评估献血者中HCV血清学阳性在临床、生化和病毒学方面的意义。
使用第三代酶联免疫吸附测定法(抗HIV 1和2、抗HCV、乙肝表面抗原)、性病研究实验室试验(VDRL)和疟疾病原虫外周血涂片对总共16250个血液单位进行强制性检测。告知抗HCV反应性阳性的献血者。对抗HCV反应性阳性的重复献血者进行详细的临床病史询问,重点关注HCV传播的危险因素。血液检测包括肝功能检查(LFT)、凝血和自身免疫指标、定性血清冷球蛋白以及HCV RNA检测。通过LFT对这些献血者每2至3个月随访一次,至少随访6个月。
我们的献血者中总体血清学阳性率为0.44%(72/16250),首次献血的年轻自愿献血者的血清学阳性率显著低于替代献血者(0.27%对0.60%)。与药物滥用(6.4%)相比,我们发现共用剃须工具或去路边理发店等轻微经皮途径(32%)是HCV传播的主要危险因素。这些献血者中均无输血史;然而,25.8%的人有一些手术史。分别有87%和71%的献血者转氨酶升高和存在HCV病毒血症。当酶联免疫吸附测定法比值>5时,观察到HCV RNA之间存在关联。
自愿献血者是安全的血液供应来源,应努力将这一宝贵来源增加到100%。对重复献血者采用简化的行为献血者筛查问卷不可取。需要对献血者进行关于HCV传播方式的宣传和教育。应告知HCV阳性献血者其病情,给予咨询并转诊至肝病专家处,且永久推迟其未来献血。